Back to Search
Start Over
Clinical utility of [ 68 Ga]Ga-labeled fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography for primary staging and recurrence detection in nasopharyngeal carcinoma.
- Source :
-
European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2021 Oct; Vol. 48 (11), pp. 3606-3617. Date of Electronic Publication: 2021 Apr 01. - Publication Year :
- 2021
-
Abstract
- Purpose: This study aimed to explore the clinical utility of [ <superscript>68</superscript> Ga]Ga-labeled fibroblast activation protein inhibitor ([ <superscript>68</superscript> Ga]Ga-FAPI) positron emission tomography/computed tomography (PET/CT) relative to [ <superscript>18</superscript> F]-fluorodeoxyglucose ([ <superscript>18</superscript> F]FDG) PET/CT and magnetic resonance imaging (MRI) for primary staging and recurrence detection in nasopharyngeal carcinoma (NPC).<br />Methods: This retrospective analysis utilized a sub-cohort of patients from a previously acquired database. Patients with NPC who underwent [ <superscript>18</superscript> F]FDG and [ <superscript>68</superscript> Ga]Ga-FAPI PET/CT between October 2019 and November 2020 were included. The radiotracer uptake and clinical staging/restaging performances of [ <superscript>18</superscript> F]FDG and [ <superscript>68</superscript> Ga]Ga-FAPI PET/CT were compared.<br />Results: Forty-five participants (39 for initial assessment, 6 for recurrence detection) were included. In treatment-naïve participants, [ <superscript>68</superscript> Ga]Ga-FAPI PET/CT showed higher radiotracer uptake than [ <superscript>18</superscript> F]FDG PET/CT in primary tumors (16.18 vs. 10.11, P < 0.001), regional lymph nodes (11.42 vs. 7.37, P < 0.001), and bone and visceral metastases (6.94 vs. 3.11, P < 0.001). Compared with the [ <superscript>18</superscript> F]FDG-based TNM stage, the [ <superscript>68</superscript> Ga]Ga-FAPI-based TNM stage was upgraded in ten patients (26%), resulting in management changes in seven patients (18%). Compared with MRI, [ <superscript>68</superscript> Ga]Ga-FAPI PET/CT upgraded and underestimated the T stage in four and two patients, respectively. In post-treatment patients, [ <superscript>68</superscript> Ga]Ga-FAPI PET/CT yielded more true-positive findings than [ <superscript>18</superscript> F]FDG PET/CT in detecting local recurrence.<br />Conclusion: [ <superscript>68</superscript> Ga]Ga-FAPI PET/CT is a promising imaging modality for the diagnosis of primary and metastatic NPC. The exact tumor geographic imaging obtained through [ <superscript>68</superscript> Ga]Ga-FAPI PET/CT may be a supplement to MRI for T staging and radiotherapy planning.<br /> (© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Details
- Language :
- English
- ISSN :
- 1619-7089
- Volume :
- 48
- Issue :
- 11
- Database :
- MEDLINE
- Journal :
- European journal of nuclear medicine and molecular imaging
- Publication Type :
- Academic Journal
- Accession number :
- 33792760
- Full Text :
- https://doi.org/10.1007/s00259-021-05336-w